GRAIL is a healthcare company focused on multi-cancer early detection (MCED) through blood-based screening. The company develops and commercializes the Galleri test, a next-generation sequencing-based blood test that can detect more than 50 types of cancer in earlier stages when treatment may be more effective. GRAIL uses population-scale clinical studies, machine learning, and advanced automation to enable early cancer detection and identification.
Grail (Biotechnology) is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2016
Employees
910–1,423
Total Funding
$9.09B
6 rounds
Latest Valuation
$7.1B
June 24, 2024
Total raised $9.09B across 6 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Acquisition by Illumina
Date
August 18, 2021
Amount
$7.1B
Valuation
$7.1B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| June 24, 2024 | Direct listing / spinoff (Nasdaq) | Not disclosed | — | None named |
| August 18, 2021 | Acquisition by Illumina | $7.1B | $7.1B | Illumina |
| May 13, 2020 | Series D | $390M | — | Canada Pension Plan Investment Board, Public Sector Pension Investment Board, Illumina |
Josh Ofman
Chief Executive Officer
Bob Ragusa
Former Chief Executive Officer (retiring June 1, 2026)
Richard Klausner
Board Member
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Guardant Health
Develops liquid biopsy tests including Shield blood test for colorectal cancer screening (FDA approved and Medicare covered) and LUNAR-2 for early colorectal cancer detection.
Freenome
Develops blood-based cancer detection and monitoring tests. Backed by Exact Sciences and Verily.
Roche
Major diagnostics and pharmaceuticals company developing cancer detection solutions.
Color Genomics
Provides genetic testing and precision medicine services.
Exact Sciences
Develops molecular diagnostics for cancer detection including Cologuard for colorectal cancer screening.
GRAIL was spun off from Illumina and began trading on Nasdaq under ticker symbol GRAL on June 25, 2024. Illumina shareholders received one share of GRAIL for every six Illumina shares held. Illumina retains a 14.5% stake in GRAIL.
Grail (Biotechnology) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Grail (Biotechnology) had a valuation of approximately $7.1B at the time of its public offering. Current market capitalization fluctuates with the share price.
Grail (Biotechnology) raised $9.09B across 6 disclosed funding rounds prior to its public listing.
Grail (Biotechnology) is headquartered in Menlo Park, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.